Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | F13A1 | P00488 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592850 | 0.88 | KDM4E (0.84) | KDM4EF13A1SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6845394 | 0.87 | KDM4E (0.70) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL6329536 | 0.87 | KDM4E (0.70) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL3203944 | 0.87 | KDM4E (0.70) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL4701625 | 0.84 | KDM4E (0.62) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL4864495 | 0.84 | KDM4E (0.66) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL10865713 | 0.83 | L3MBTL1 (0.66) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL7858 | 0.82 | KDM4E (0.69) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL10451965 | 0.82 | KDM4E (0.64) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL16017577 | 0.82 | PLK1 (0.64) | KDM4EF13A1KMT2ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022053541-A1 | COMPOUNDS FOR USE AS APPETITE SUPPRESSANT | ERACAL THERAPEUTICS LTD. (CH) | 2022-03-17 | — | — | WO | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3694840-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | Hoffmann-La Roche AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019072785-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| EP-2780013-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013075084-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-1523473-B1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009547-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| CN-1384830-A | Novel spiroheterocyclic compounds as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMA (US) | 2002-12-11 | — | — | CN | disclosed |
| US-4402975-A | ANTIULCER AGENTS | TEIJIN LIMITED (JP) | 1983-09-06 | — | — | US | disclosed |
| US-4238506-A | SECONDARY OR TERTIARY AMIDE-SUBSTITUTED | BOEHRINGER MANNHEIM GMBH (DE) | 1980-12-09 | — | — | US | disclosed |
| US-4221815-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4158063-A | Acylamino(alkyl)benzene derivatives and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-12 | — | — | US | disclosed |
| US-4113871-A | HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS | BOEHRINGER MANNHEIM GMBH (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | KDR, FLT1, EGFR | KDM4E 1812/4885F13A1 3795/4885KMT2A 2965/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | KDM4E 2009/4885F13A1 2706/4885KMT2A 1679/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | KDM4E 2009/4885F13A1 2706/4885KMT2A 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.